Biomaterial Database

Paronychia in patients receiving antiretroviral therapy for human immunodeficiency virus infection. 2000

S Sibel, and A Macher, and E Goosby

UI	MeSH Term	Description	Entries
D008297	Male		Males
D008875	Middle Aged	An adult aged 45 - 64 years.	Middle Age
D010304	Paronychia	An inflammatory reaction involving the folds of the skin surrounding the fingernail. It is characterized by acute or chronic purulent, tender, and painful swellings of the tissues around the nail, caused by an abscess of the nail fold. The pathogenic yeast causing paronychia is most frequently Candida albicans. Saprophytic fungi may also be involved. The causative bacteria are usually Staphylococcus, Pseudomonas aeruginosa, or Streptococcus. (Andrews' Diseases of the Skin, 8th ed, p271)	Paronychias
D005260	Female		Females
D006801	Humans	Members of the species Homo sapiens.	Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328	Adult	A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available.	Adults
D015658	HIV Infections	Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS).	HTLV-III Infections,HTLV-III-LAV Infections,T-Lymphotropic Virus Type III Infections, Human,HIV Coinfection,Coinfection, HIV,Coinfections, HIV,HIV Coinfections,HIV Infection,HTLV III Infections,HTLV III LAV Infections,HTLV-III Infection,HTLV-III-LAV Infection,Infection, HIV,Infection, HTLV-III,Infection, HTLV-III-LAV,Infections, HIV,Infections, HTLV-III,Infections, HTLV-III-LAV,T Lymphotropic Virus Type III Infections, Human
D019380	Anti-HIV Agents	Agents used to treat AIDS and/or stop the spread of the HIV infection. These do not include drugs used to treat symptoms or opportunistic infections associated with AIDS.	AIDS Drug,AIDS Drugs,Anti-AIDS Agents,Anti-AIDS Drug,Anti-HIV Agent,Anti-HIV Drug,Anti-AIDS Drugs,Anti-HIV Drugs,Agent, Anti-HIV,Agents, Anti-AIDS,Agents, Anti-HIV,Anti AIDS Agents,Anti AIDS Drug,Anti AIDS Drugs,Anti HIV Agent,Anti HIV Agents,Anti HIV Drug,Anti HIV Drugs,Drug, AIDS,Drug, Anti-AIDS,Drug, Anti-HIV,Drugs, AIDS,Drugs, Anti-AIDS,Drugs, Anti-HIV

Related Publications

S Sibel, and A Macher, and E Goosby

External ophthalmoplegia in human immunodeficiency virus-infected patients receiving antiretroviral therapy.

December 2012, Journal of AAPOS : the official publication of the American Association for Pediatric Ophthalmology and Strabismus,

S Sibel, and A Macher, and E Goosby

Antiretroviral therapy for human immunodeficiency virus infection in 1997.

May 1997, The Western journal of medicine,

S Sibel, and A Macher, and E Goosby

Development of tuberculosis in human immunodeficiency virus infected patients receiving antiretroviral therapy.

September 2014, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease,

S Sibel, and A Macher, and E Goosby

Part XV. Antiretroviral therapy for human immunodeficiency virus infection.

November 2007, The Journal of the Oklahoma State Medical Association,

S Sibel, and A Macher, and E Goosby

Antiretroviral Therapy for Prevention of Human Immunodeficiency Virus Infection.

July 2016, The Medical clinics of North America,

S Sibel, and A Macher, and E Goosby

Influenza vaccination of human immunodeficiency virus 1-infected patients receiving antiretroviral therapy.

February 2001, Acta virologica,

S Sibel, and A Macher, and E Goosby

Sarcoid-like pulmonary disorder in human immunodeficiency virus-infected patients receiving antiretroviral therapy.

June 1999, American journal of respiratory and critical care medicine,